Use the hyperlinks, where available to access additional clinical trial information.
Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
Odonate Therapeutics, Inc.
This is a single arm, non-randomised trial. Eligible participants will receive Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and Capecitabine at a predetermined dose cycle.